1. Home
  2. AAUC vs RCUS Comparison

AAUC vs RCUS Comparison

Compare AAUC & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AAUC

Allied Gold Corporation

HOLD

Current Price

$30.58

Market Cap

3.4B

Sector

N/A

ML Signal

HOLD

Logo Arcus Biosciences Inc.

RCUS

Arcus Biosciences Inc.

HOLD

Current Price

$23.08

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AAUC
RCUS
Founded
N/A
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
2.8B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
AAUC
RCUS
Price
$30.58
$23.08
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$28.89
AVG Volume (30 Days)
679.1K
1.4M
Earning Date
03-27-2026
02-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,074,850,000.00
$240,000,000.00
Revenue This Year
$80.45
N/A
Revenue Next Year
$54.02
N/A
P/E Ratio
N/A
N/A
Revenue Growth
45.41
N/A
52 Week Low
$7.02
$6.50
52 Week High
$29.84
$26.40

Technical Indicators

Market Signals
Indicator
AAUC
RCUS
Relative Strength Index (RSI) 81.53 52.59
Support Level $26.41 $20.70
Resistance Level $25.20 $23.40
Average True Range (ATR) 1.05 1.44
MACD 0.38 0.03
Stochastic Oscillator 94.49 61.75

Price Performance

Historical Comparison
AAUC
RCUS

About AAUC Allied Gold Corporation

Allied Gold Corp is a company focused on gold mining activities in Africa. Allied has three mines and several development and exploration projects in Africa where it has operating experience. Operations are located in Cote d'Ivoire, Mali, and Ethiopia. The company expands and optimizes initiatives at existing operating mines, the development of new mines, the advancement of its exploration properties, and, targeting other consolidation opportunities with a focus on Africa.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Share on Social Networks: